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Azathioprine (AZA) is a thiopurine prodrug which is widely used in patients with inﬂammatory bowel
disease (IBD). However, the use is limited in oneethird of patients because of adverse drug reactions
(ADRs) or a lack of clinical response. It has been considered that the polymorphic enzyme thiopurine S
emethyltransferase (TPMT) plays an important role in the in vivo process of AZA and the occurrence of
its myelotoxicity. Glutathione Setransferase (GST) mutation is another pharmacogenetic polymorphism
which is probably involved in AZA metabolism and tolerance. The aim of this study was to investigate the
association among GST polymorphism, enzyme activity and AZAerelated ADRs in Chinese Han patients
with IBD.
We found that the patients who became neutropenic had a signiﬁcantly higher GSTs activity when
compared with of the patients who did not develop ADRs (analysis of variance, P < 0.001). There was also
a signiﬁcant underrepresentation of GSTP1*e105V allele among patients developing ADRs (odds ratio
[OR] ¼ 0.125, 95% conﬁdence interval [CI] ¼ 0.022e0.709, P ¼ 0.0012).
The patients with higher GST activity constituted a pharmacogenetic high risk group for leucopenia
during AZA treatment. GSTeP1 Ile105/Ile105 genotype appeared to be a promising marker indicating
predisposition to AZAerelated ADRs.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Azathioprine (AZA) is one of the most widely used immuno-
suppressive agents in the treatment of several autoimmune dis-
eases, like inﬂammatory bowel disease (IBD). In clinical practice,
despite its efﬁcacy in maintaining remission in IBD is largely
accepted, adverse drug reactions (ADRs) may occur in 15%e38% ofhe First Afﬁliated Hospital of
0297859.
iu), echonony@foxmail.com
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).patients and often require the withdrawal of therapy. AZA is a
prodrug which can be metabolized to 6ethioguanine nucleotides
(6eTGN) to exert its immunosuppressive action. After oral
administration, AZA is quickly absorbed from the digestive tract
and does not cross the bloodebrain barrier (1). The oral bioavail-
ability of AZA is about 27%e83%, and 88% of AZA converted to
mercaptopurine by the catalytic action of glutathione
Setransferases (GSTs). Although this reaction is considered a non-
eenzyme action or is ignored (2,3), some studies have certiﬁcated
that GST may participate in the reaction (4e6).
As a result of catabolism of AZA to the active metabolite 6-TGNs,
which is mediated by several enzymes, AZA can induce variable
adverse drug reactions. One of the important enzymes is thiopurinenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
H. Liu et al. / Journal of Pharmacological Sciences 129 (2015) 95e10096(S)emethyltransferase (TPMT) which is involved in the metabolism
of the inactive produces (7). The genotype polymorphisms may
explain a part of individual differences of ADRs (8). However, the
frequencies of TPMT mutations in Chinese population are very low.
It indicated that there could be other reasons to explain the indi-
vidual differences of ADRs in Han race. Another relative enzyme is
inosine triphosphate pyrophosphatase (ITPA) enzyme. Some
studies have shown that ITPA 94C >A homozygous alleles were at
high risk to develop AZAerelated gastrointestinal toxicity and
Fluelike symptoms in Chinese patients with kidney transplant (9).
However, only two enzymes could not clearly explain all the ADRs
of AZA. GST might be one of the candidate factors in all of the en-
zymes that inﬂuence AZA metabolism and toxicity.
GST comprise a supergene family of enzymes and catalyze the
conjugation of reduced glutathione with various electrophilic
compounds including environmental carcinogens and therapeutic
agents (10). Several studies have been conducted on the role of
polymorphisms of genes regulating cytosolic GST, including GSTT1,
GSTM1, GSTP1, and GSTA1. For GSTM1 genes, deletions result in no
enzyme activity range from 41.7% to 55.5% in Asians, from 13.1% to
54.5% in Caucasians, 46.7% in AfricaneAmericans. Meanwhile the
reported prevalence rates of GSTT1 null genotype were 41.9%e52%
in Asians, 11.1%e28.6% in Caucasians, 26.7% in AfricaneAmericans,
and 36.6% in Africans with no enzyme activity deletion mutation
(11,33). The allelic variants of GSTP1 encode enzymes with reduced
catalytic activity. While for GSTP1 polymorphism (Val/Val homo-
zygote and IIe/Val heterozygote), the prevalence rates from pub-
lished data were 9%e12.6% and 40.8%e30.1% in Caucasians, 13.3%e
19% and 38%e49% in AfricaneAmericans, and 0e5.4% and 25%e28%
in Asian, respectively (12,34). For GSTA1 (Ce69T) genes, the Previ-
ous studies showed that the rate of polymorphism (T/T homozygote
and C/T heterozygote) were 14%e19% and 48%e50% in Caucasians,
13% and 26% in AfricaneAmericans, 2.7%e0.7% and 26.5%e24.3% in
Asians respectively (13e15).
Data on the inﬂuence of the four genetic polymorphisms and
enzyme activity are lacking among the Chinese population with
IBD. Given this background, we evaluated the relationships among
GST polymorphism, enzyme activity and AZAerelated ADRs in
Chinese Han patients with IBD.
2. Patients and methods
2.1. Patient selection
One hundred and twelve Han Chinese subjects (71 men and 41
women; mean age 32 ± 15.6 years, range 18e63 years) were
recruited in this study and diagnosed with IBD by the Department
of Gastroenterology Outpatient Clinic at the First Afﬁliated Hospital
of Sun Yatesen University, Guangzhou, China.
Diagnoses of Crohn's disease (CD) and ulcerative colitis (UC)
were established by standard clinical, radiological, histological, and
endoscopic criterion. The conﬁrmation of IBD required a thorough
history, a physical examination and laboratory tests, including a
complete blood cell count, chemistry panel and urinalysis, and
serologic tests.
The initial dose of the patients was 1 mg/kg daily for AZA
(Imuran, GlaxoSmithKline®) in the ﬁrst week, and then add to
2 mg/kg daily for AZA during the following treatments and the
regimen would be withdrawal if AZA related ADRs occurred. The
minimum follow up of the patients that did not develop ADRswas 1
year.
Twentyethree patients (CD 5, UC 18) were on concomitant
treatment with 5eAminosalicylic acid (5eASA), ﬁfteen patients (CD
4, UC 11) were on concomitant treatment with inﬂiximab and all
112 patients were in combination with a regimen of steroids.Within 3months prior to the study, none of the patients included in
the study had received a blood transfusion. Patients who received
concomitant medications that might affect the metabolism of AZA,
such as cyclosporine, methotrexate or allopurinol, or liver micro-
somal enzyme inducers or inhibitors within the last 3 months, who
have insufﬁciency of function in heart, liver or kidney, have preg-
nancy and have mutation genotype of TPMT, were excluded.
All the necessary clinical information including laboratory
data, the dose and ADRs were retrospectively estimated by
screening of patients' medical records. Demographic and routine
clinical data were obtained from hospital outpatient clinic com-
puter systems.
For analysis of the adverse effects inducted by AZA, leucopenia
was deﬁned as white blood cell (WBC) count <3.5  109/L and
neutropenia was deﬁned as neutrophils count <1.5  109/L. Liver
toxicity was deﬁned as alanine aminotransferase (ALAT), gal-
actosylhydroxylysyl glucosyltransferase (GGT), or alkaline phos-
phatase more than twice the normal limit. Pancreatitis was deﬁned
as severe abdominal pain accompanied by serum amylase level
more than twice the normal limit. Fluelike symptoms included
fever, headache, courbature and arthralgia. Gastrointestinal intol-
erance was deﬁned as nausea, vomiting and abdominal pain.
2.2. Genotyping study of GSTM1, GSTT1, GSTP1 and GSTA1
1 ml venous blood samples (EDTA anticoagulation) were ob-
tained prior to treatment. Blood samples (1 ml each) were drawn
into tubes containing EDTA when prior to starting treatment for
genotyping detection. Genomic DNA was extracted using Mini
NucleoSpin® Blood Kit (MachereyeNagel GmbH &Co. KG). The
GSTM1 and GSTT1 genotypes were determined by polymerase chain
reaction (PCR) ampliﬁcation as previously reported (16). GSTP1 and
GSTA1 genotypes were determined by PCReRFLP method as
described (11).
2.3. Determination of erythrocyte GSTs activity
Blood samples were collected in EDTA tubes and centrifuged at
800 g for 10 min at 4 C to isolate erythrocytes (11). After washed
the resultant erythrocytes three times with an isotonic sodium
chloride solution, isolate erythrocytes were gently resuspended in
2ml of physiological saline and then the hemoglobin concentration
were detected. Erythrocytes were lysed with cold distilled water
(1:4, v/v) and centrifuged at 13,000 g for 10 min at 4 C. The
hemolysates were stored at 80 C until analysis.
Total erythrocytes GST activity was measured by means of an
artiﬁcial substrate 1echloroe2, 4edinitroebezene (CDNB) in
erythrocytes lysate according to the procedure described with
previously described modiﬁcations (17).
GSTs enzyme activity was expressed as the formation of 1 mol of
CDNBeGSH per minute of incubation. The unit of GST was
normalized per gram of hemoglobin.
2.4. Statistical analyses
Statistical analyses were performed by using SPSS for Windows
(Version 16.0). Two sided Fisher's exact test or Pearson's Chies-
quare test were applied in a crosstab of any mutation in the GST
gene vs. any complication of AZA use. Comparison of continuous
variables was done using the nonparametric twoesided Wilcoxon
rank sum test. The association between GST activity and the inci-
dence of ADRs were examined by logistic regression analysis,
adjusting for age, sex. The odds ratio (OR) and its 95% CI were used
to describe the strength of association, with P < 0.05 considered to
be statistically signiﬁcant.
Fig. 1. The distribution of GSTs activity in 112 IBD patients. N ¼ 112, 0.32 to 9.95
(3.96 ± 1.72).
Table 2
Erythrocyte GSTs activity in different adverse drug reactions groups in IBD patients
(U/gHb).
Leucopeniaa Gastrointestinal
toxicityb
Fluelike
symptomsc
Without ADRs
Number 22 7 4 79
GSTs activity
(mean ± SD)
7.134 ± 3.097 5.796 ± 1.860 5.296 ± 1.467 4.687 ± 1.834
Pevalued 0.001 0.075 0.366
a Five patients developed two leucopenia and gastrointestinal toxicity
simultaneously.
b Three patients developed gastrointestinal toxicity and ﬂuelike symptoms
simultaneously.
c Two patients developed two leucopenia and ﬂuelike symptoms simultaneously.
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3.1. Demographic information and clinical characteristics
All 112 Han Chinese patients with diagnosed IBD and adminis-
trationwith AZAwere included in the study. Themean bodyweight
was 51.5 kg (range 33.5e72.0 kg). During the stage of therapy of
AZA, leucopenia occurred in 22 patients (10 males and 12 females),
gastrointestinal toxicity occurred in 11 patients (6 males and 5 fe-
males) and 4 patient developed leucopenia simultaneously. Flue-
like symptoms occurred in 9 patients (6 males and 3 females) and 5
patient developed leucopenia simultaneously. None of the patients
developed pancreatitis or hepatotoxicity. The data for age, sex, body
weight, duration of AZA, and concomitant drugs showed no sig-
niﬁcant inﬂuence on the frequencies of ADRs during AZA therapy
(P > 0.05). Characteristics of patients were shown in Table 1.
3.2. Phenotype and genotyping of GST
The characteristic pattern in Fig. 1 reveals the GSTs activity of
erythrocyte lysates in the 112 Han Chinese IBD patients. It showed a
leptokurtic positively skewed distribution which could be
normalized by logarithmic transformation. On logarithmic scale,
the range of GSTs activity was from 0.32 to 9.95 U/gHbwith a mean
value of (3.96 ± 1.72) U/gHb. In consideration of gendererelated
differences between groups, erythrocyte GSTs activity in the males
were higher than the females, but there was no statistical signiﬁ-
cance (3.72 ± 1.08 versus 4.08 ± 0.95 U/gHb, P¼ 0.076). There was a
signiﬁcant difference in the mean erythrocyte GSTs activity be-
tween with and without leucopenia groups. Erythrocyte GSTs ac-
tivity in the patients with leucopeniawere signiﬁcantly higher than
in the patients without leucopenia (3.49 ± 0.09 versus
3.14 ± 0.04 U/gHb, P ¼ 0.001) (Table 2).
The GSTs activity in subjects inherited of GSTP1 Ile 105Val and
GSTP1 Val 105Val was gently higher than that of carriers GSTP1 Ile105
Ile (P¼ 0.072). However the differences which were also showed in
Table 3 were not found in the other three SNPs in GST genotype.
3.3. Relationships between GST genotypes and the risk of ADRs to
AZA
The associations between GSTM1, GSTT1, GSTP1, GSTA1, ADRs
and the respective ORs are presented in Table 4. The frequencies of
GSTM1 and GSTT1 null genotypes in the patients were 52.7% and
50.9%, respectively. The frequencies of GSTA1 C/C, C/T and T/T ge-
notypes were 78.5%, 19.6% and 0.9%, respectively. The only genetic
polymorphism in GSTP1 was Ile105Val in exon 5. The genotype
distributions of this locus were 65.2% of Ile105/Ile105, 33.0% of
Ile105/Val105, and 1.8% in Val105/Val105, respectively. They wereTable 1
Characteristics of 112 patients with IBD.
Number Median/range
ALL 112
Sex
Male 71
Female 41
Diagnosis
CD 87
UC 25
Combination
5eASA 23
Inﬂiximab 15
Age (years) 18e63 32
Weight (kg) 30e75 51.4all in HardyeWeinberg equilibrium. The overall frequency of
defective alleles obtained in the present study is comparable to
that reported for these genes in other populations of Chinese
origin (16).
The incidence of leucopenia was signiﬁcantly higher in the pa-
tients with GSTP1 Ile105/Val105 or GSTP1 Val105/Val105 genotypes
than in the patients with the GSTP1wild type genotype (OR¼ 0.161,d Compared with Without ADRs.
Table 3
Erythrocyte GSTs activity in Han Chinese IBD patients with different genotypes of
GSTs (U/g Hb).
Gene n GSTs activity (mean ± S.D.) Pevalue
GSTM1 (e) 59 3.79 ± 1.51 0.290
GSTM1 (þ) 53 4.15 ± 1.99
GSTT1 (e) 57 4.05 ± 1.92 0.596
GSTT1 (þ) 55 3.87 ± 1.58
GSTP1 (I/I) 73 4.23 ± 1.72 0.025
GSTP1 (I/V or V/V) 39 3.45 ± 1.71
GSTA1 (C/C) 89 4.04 ± 1.74 0.340
GSTA1 (C/T or T/T) 23 3.66 ± 1.84
Total 112 3.96 ± 1.72
Table 4
GSTM1, GSTT1, GSTP1 and GSTA1 genotype and adverse drug reactions of treatment with AZA in IBD patients.
Genotype Leucopeniaa Gastrointestinal toxicityb Fluelike symptomsc Without ADRs
GSTM1(e) (n ¼ 59) 7 6 2 47
GSTM1(þ) (n ¼ 53) 15 5 7 34
Odds ratio (95% CI) 0.338 (0.124e0.917) 0.904 (0.226e3.619) 0.207 (0.040e1.057)
Pevalue 0.029 0.887 0.041
GSTT1(e) (n ¼ 57) 14 8 4 43
GSTT1 (þ) (n ¼ 55) 8 3 5 30
Odds ratio (95% CI) 2.188 (0.827e5.788) 3.333 (0.824e13.482) 1.000 (0.250e3.998)
Pevalue 0.110 0.078 1.000
GSTP1(I/I) (n ¼ 73) 20 5 5 50
GSTP1(I/VorV/V) (n ¼ 39) 2 6 4 31
Odds ratio (95% CI) 0.161 (0.035e0.738) 1.935 (0.544e6.882) 1.290 (0.322e5.175)
Pevalue 0.009 0.302 0.731
GSTA1(C/C) (n ¼ 89) 15 10 6 65
GSTA1(C/T or T/T) (n ¼ 23) 7 1 3 16
Odds ratio (95% CI) 1.896 (0.663e5.422) 0.406 (0.048e3.409) 2.031 (0.458e9.012)
Pevalue 0.254 0.682 0.392
a Five patients developed leucopenia and gastrointestinal toxicity simultaneously.
b Three patients developed gastrointestinal toxicity and ﬂuelike symptoms simultaneously.
c Two patients developed leucopenia and ﬂuelike symptoms simultaneously.
H. Liu et al. / Journal of Pharmacological Sciences 129 (2015) 95e1009895% CI ¼ 0.035e0.738, P ¼ 0.009). It indicated that there was a
signiﬁcant correlation between GSTM1 wide genotype and
AZAerelated leucopenia and Fluelike symptoms (OR ¼ 0.338, 95%
CI ¼ 0.124e0.917, P ¼ 0.029 and OR ¼ 0.207, 95% CI ¼ 0.040e1.057,
P ¼ 0.041, respectively).
There were no signiﬁcant differences in leucopenia, gastroin-
testinal intolerance and Fluelike symptoms between the patients
carrying GSTT1 (þ) and GSTT1 (e) genotypes and the patients car-
rying GSTA1 C/C, C/T and T/T (P > 0.05).
3.4. Risk factors associated with ADRs to pulsed AZA therapy in IBD
patients
A multiple logistic regression analysis was carried out to eval-
uate the risk factors associated with ADRs to pulsed AZA therapy in
IBD patients. The logistic regressionmodel considered the potential
risk factors, including gender, age, GSTs activity, GSTM1, GSTT1,
GSTP1 and GSTA1 genotype, Diagnosis, and the considered for leu-
copenia, gastrointestinal toxicity, Fluelike symptoms. It appeared
that the GSTT1 and GSTA1 null mutations did not affect the inci-
dence of AZA induced adverse effects in our study population. This
result conﬁrmed an independent signiﬁcant association between
the occurrence of AZAeinduced ADRs and the variable GSTT1 ge-
notype (for the GSTP1 Ile105Val and GSTP1 Val105Val105 genotype
OR ¼ e0.070, 95% CI ¼ e0.010e0.49, P ¼ 0.0073). All other risk
factors were not signiﬁcantly associated with the comparison of
AZAerelated ADRs (Table 5).Table 5
Odds ratios with conﬁdence intervals for the independent variables in the Logistic regre
Factors Leucopenia Gastro
OR 95% CI OR
Age 1.007 0.957e1.059 0.986
Gender 0.369 0.111e1.226 0.362
Type of IBD 2.613 0.455e14.993 1.252
GST activity 11.680* 1.665e81.925 3.863
GSTM1 0.404 0.117e1.393 1.473
GSTT1 2.627 0.763e9.043 3.658
GSTP1 0.125* 0.022e0.709 3.331
GSTA1 1.918 0.517e7.125 0.116
Combination
5eASA 4.254 0.923e19.615 6.263
Inﬂiximab 1.199 0.164e8.742 0.261
*P < 0.05.4. Discussion
AZA plays a prominent place as mainstay therapy of IBD. How-
ever, in clinical practice, patients often require withdrawal of the
drug because of ADRs (18). Nonfunctional genetic mutations of
TPMT is known to modulate the clinical response to thiopurines in
kidney transplant recipients have an increased risk of myelotoxicity
during treatment with AZA (19). However, not all adverse effects
can be related to a mutated TPMT genotype (20). What is more, the
frequencies of TPMT genotype of mutations in Caucasians popula-
tion are higher than in Chinese population. Excepted TPMT poly-
morphisms, the other factors may be responsible for the
development of toxicity. No case with TPMTmutationwas found in
our study. Therefore, other genetic and epigenetic factors must play
a role in the incidence of the ADRs, including ITPA (21), hypoxan-
thine guanine phosphoribosyltransferase (HPRT) (22), and GST (6).
The GSTs are a group of enzymes involved in AZA biotransfor-
mation by the conjugation of electrophiles with GSH. To our
knowledge, this is the ﬁrst study of GSTs activity in erythrocytes in
patients with IBD. The GSTs activity of erythrocyte lysates showed a
leptokurtic positively skewed distribution that could be normalized
by logarithmic transformation both in the health Han Chinese
population and in the Han Chinese IBD patients. A signiﬁcant as-
sociation between AZAerelated leucopenia and the GSTs activity in
erythrocytes was found in this study. The patients in the leucopenia
group have shown a higher GSTs activity than those in the without
ADRs group. On the other hand, we found that there were nossion model for the occurrence of AZAeinduced adverse drug reactions.
intestinal toxicity Fluelike symptoms
95% CI OR 95% CI
0.927e1.049 1.030 0.959e1.106
0.077e1.713 0.734 0.162e3.324
0.212e7.401 4.069 0.357e46.360
0.518e28.789 2.999 0.450e19.968
0.330e6.564 0.212 0.038e1.175
0.743e18.023 0.570 0.127e2.565
0.772e14.363 1.937 0.475e7.896
0.007e1.984 1.507 0.274e8.280
1.167e33.611 0.863 0.119e6.252
0.018e3.733 0.742 0.062e8.905
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symptoms group. A positive correlation between GSTs activity and
the risk of leucopenia has been found. Indeed, as patients with
higher GSTs activity have an increasedmetabolic activity during the
treatment with AZA, the metabolites induced leucopenia are
accrescence.
Since AZA are mainly metalized by multiple GST (4,23e25),
including GTSM1, GSTT1, GSTP1 and GSTA1, we hypothesized that
the four genetic polymorphisms of might lead to increased ADR to
AZA therapy in IBD patients. This investigation shows that there is a
signiﬁcant association between GSTP1, GSTM1 wild genotype and
AZAerelated leucopenia.
Analyzing all the factors that may contribute to AZAerelated
leucopenia, we found that patients carrying GSTP1 wildetype ge-
notype and high GST activity are at signiﬁcantly higher risk of
AZAerelated leucopenia. We speculate that the GSTP1*e105V mu-
tation is likely to degrade the GSTs activity in erythrocyte due to
decreased concentrations of 6eMP at the ﬁrst step of metabolism.
After oral application of AZA, very little it is detectable in patient
plasma (26e28). Similar observations have been reported in mice
(29) and the rhesus monkey (30). It was that indicated erythrocytes
play a major role in this step in vivo. In the other hand, in the in-
testinal mucosa of AZAetreated mice the extremely high 6eMP
concentrations were detected, which concluded a substantial
transformation of AZA to 6eMP in the gut wall (31). Moreover,
studies have shown that GST enzyme super family exist differences
in tissue distribution, metabolic activity and the substrate speci-
ﬁcity of these enzymes. GSTP1 (originally found in the placenta) is
mainly expressed in the lung, kidney, GI tract, erythrocytes and
cancer cells. Abundant GSTM1 and GSTA1 are present in the liver
and lymphocytes but in erythrocytes (32). GSTP1*e105V mutation
has an association with reduced erythrocyte enzyme activity in
Chinese (16). Subjects with GSTP1 wild genotype and higher
erythrocytes GSTs activity might produce more 6eMP, which in
turn might result in the higher drug sideeeffects observed. These
ﬁndings, from our study, indicate that after oral administration of
AZA, GSTP1 subtype could explain the inﬂuence of the GST geno-
type on the incidence of leucopenia.
It is widely accepted that GSTs play a major role in detoxiﬁcation
and defense against toxic, carcinogenic and other compounds (33).
The thiolysis of AZA to 6-MP consumes GSH. It is suggest an indirect
ability to induce oxidative stress, mediated primarily by GSH con-
sumption during AZA conversion to mercaptopurine. Al Maruf A
et al. have shown that AZA-induced cytotoxicity may be partly due
to ROS formation and GSH depletion that resulted in oxidative
stress and mitochondrial injury in isolated rat hepatocytes (34).
GSTs might appear to exert a statistically signiﬁcant and biologi-
cally relevant impact on the incidence and the variety of adverse
effects during AZA therapy. Stocco et al. found that patients car-
rying the GSTM1 wildetype genotype have a relationship with
ADRs (6). However, we found that GSTM1wildetype genotype have
a relationship with leucopenia and Fluelike symptom. Following
adjustment for other potential risk factors, it shown that the GSTM1
genotype did not affect the incidence of all ADRs to AZA therapy.
The result suggested GSTM1 genotype does not appear to be a main
factor that at higher risk for leucopenia during AZA therapy.
Additionally, In our study there were 23 patients taking AZA
combined with 5-ASA, a signiﬁcant relationship between the AZA
treatment in combination with 5eASA and GI toxicity have been
found in multiple logistic regression analysis, probably due to the
5eASA related side effect. In a prospective study which was done
by de Boer et al. combination with 5-aminosalicylic acid was one
risky factor of all ADRs. Whatever, 5-aminosalicylic acid does not
raise the incidence of ADRs by affecting the GSTs activity in our
study. The molecular mechanism should be studied further.Kazuhiko Uchiyama et al found a new SNPS that provides helpful
information on genetic biomarkers to reduce the number of ADRs
in AZA/5-ASA treatment of IBD patients (35).
Furthermore, it is conceivable that GSTP1 wildetype frequency
is higher in Chinese populations (71%e78%) than in Caucasian
populations (68%e70%) (36e38). The GSTs erythrocyte activity may
higher in Chinese population which may result in higher concen-
tration of metabolize of AZA than in Caucasian populations. The
high concentration of metabolize of AZA leads to an increased risk
of myelotoxicity. Therefore, the GSTP1 detection is more valuable in
Chinese population than Caucasian populations.
5. Conclusion
This retrospective study has suggest that the IBD patients in Han
Chinese population and with a high erythrocyte GSTs activity or a
wildetype GSTP1 genotype could have a greater risk of developing
leucopenia during treatment with AZA. This study shows that GST
genotype and phenotype detection may play an important role in
reducing the risk of AZAerelated leucopenia. But there is not
enough evidence to explain the relationships between GST and
other adverse effects.
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